In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of
doublet-targeted agents versus single agent is not clear. A systematic review and …

Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced
non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials - PMC Back …

Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …

Background Combining targeted therapy has been extensively investigated in previously
treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …

Purpose This phase II study evaluated efficacy of single-agent erlotinib for chemotherapy-
naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based
therapies (erlotinib+ placebo, erlotinib+ tivantinib, erlotinib+ celecoxib, erlotinib+ …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …